Inicio / Oncología / Abstracts de oncología / Circulating tumour DNA…

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

0 / 5 (0 votos)
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

The Lancet Oncology

Fecha de publicación: September 10, 2020

DOI: https://doi.org/10.1016/S1470-2045(20)30444-7

Autores: Prof Nicholas C Turner, MD , Belinda Kingston, MB, Lucy S Kilburn, MSc, Sarah Kernaghan, BSc, Prof Andrew M Wardley, MD, Iain R Macpherson, MD et al.

Background: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and the ability of ctDNA testing to select patients for mutation-directed therapy.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.